These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
8. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana. Adjapong G; Hale M; Garrill A Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642 [TBL] [Abstract][Full Text] [Related]
9. Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis. Ge G; Yang Z; Li D; Zhang N; Chen B; Shi D Front Immunol; 2022; 13():959740. PubMed ID: 35967437 [TBL] [Abstract][Full Text] [Related]
10. [Vulvovaginal candidiasis: An old disease with new challenges]. Miró MS; Rodríguez E; Vigezzi C; Icely PA; Gonzaga de Freitas Araújo M; Riera FO; Vargas L; Abiega C; Caeiro JP; Sotomayor CE Rev Iberoam Micol; 2017; 34(2):65-71. PubMed ID: 28431891 [TBL] [Abstract][Full Text] [Related]
11. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.]. Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489 [TBL] [Abstract][Full Text] [Related]
12. Candida vaccines development from point view of US patent application. Wang SJ Hum Vaccin; 2011 Nov; 7(11):1165-71. PubMed ID: 22048114 [TBL] [Abstract][Full Text] [Related]
13. Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes. Lin S; Chen R; Zhu S; Wang H; Wang L; Zou J; Yan J; Zhang X; Farmakiotis D; Tan X; Mylonakis E Mycopathologia; 2018 Aug; 183(4):679-689. PubMed ID: 29572768 [TBL] [Abstract][Full Text] [Related]
14. Vulvovaginal candidiasis in a Flemish patient population. De Vos MM; Cuenca-Estrella M; Boekhout T; Theelen B; Matthijs N; Bauters T; Nailis H; Dhont MA; Rodriguez-Tudela JL; Nelis HJ Clin Microbiol Infect; 2005 Dec; 11(12):1005-11. PubMed ID: 16307555 [TBL] [Abstract][Full Text] [Related]
16. Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis. MacAlpine J; Lionakis MS Cell Host Microbe; 2024 Oct; 32(10):1654-1667. PubMed ID: 39389030 [TBL] [Abstract][Full Text] [Related]
17. Invasive candidiasis in immunocompromised hospitalized patients. Sims CR; Ostrosky-Zeichner L; Rex JH Arch Med Res; 2005; 36(6):660-71. PubMed ID: 16216647 [TBL] [Abstract][Full Text] [Related]
18. New immunotherapeutic strategies to control vaginal candidiasis. Magliani W; Conti S; Cassone A; De Bernardis F; Polonelli L Trends Mol Med; 2002 Mar; 8(3):121-6. PubMed ID: 11879772 [TBL] [Abstract][Full Text] [Related]
19. Distinct protective host defenses against oral and vaginal candidiasis. Fidel PL Med Mycol; 2002 Aug; 40(4):359-75. PubMed ID: 12230215 [TBL] [Abstract][Full Text] [Related]
20. Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection. Ray A; Ray S; George AT; Swaminathan N Cochrane Database Syst Rev; 2011 Aug; (8):CD008739. PubMed ID: 21833970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]